# Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
Canonical URL: https://biopharmsignal.com/news/BRKR/bruker-showcases-expanding-microbiology-and-infection-diagnostics-portfolio-at-asm-microbe-2026
Ticker: BRKR
Company: Bruker
Source: Bruker
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.bruker.com
## Summary

At ASM Microbe 2026, Bruker Corporations (Nasdaq: BRKR) Microbiology Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. MALDI Biotyper(r) sirius CA System, delivering high‑throughput microbial identification to support efficient clinical laboratory workflows and improved diagnostic turnaround times During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper (r) CA System enabled by FDA Claims 7 and 8, supporting broader and more confident microbial identification in clinical laboratories. These enhancements include the MBT Compass (r) HT CA software, MBT FAST(tm) Shuttle US IVD, and an expanded FDA-cleared reference library covering 549 clinically validated microbial species across bacteria, anaerobes, and

## Article Body
IR Home Company Overview

Press Releases

Financial Info Quarterly Results

SEC Filings

Annual Reports & Proxy Statements

Annual Meeting Materials

Events & Presentations

Corporate Governance Management Team

Board of Directors

Committee Composition

Governance Documents

Stock Info Stock Quote & Chart

Historical Stock Quote

Analyst Coverage

Dividend History

IR Resources Contact Investor Relations

FAQs

Email Alerts

RSS

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

June 4, 2026

At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics.

MALDI Biotyper® sirius CA System, delivering high‑throughput microbial identification to support efficient clinical laboratory workflows and improved diagnostic turnaround times

During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper ® CA System enabled by FDA Claims 7 and 8, supporting broader and more confident microbial identification in clinical laboratories. These enhancements include the MBT Compass ® HT CA software, MBT FAST™ Shuttle US IVD, and an expanded FDA-cleared reference library covering 549 clinically validated microbial species across bacteria, anaerobes, and yeasts.

Bruker also highlights its focus on bloodstream infection and sepsis diagnostics, with a new vision to advance rapid antimicrobial susceptibility testing (AST) in clinical microbiology. Together with the MALDI Biotyper ® CA System and the Bruker Arc™ automated sample preparation solution for positive blood cultures, this innovative rapid AST workflow under development is expected to enable faster, actionable diagnostics to support earlier clinical decision-making in critically ill patients.

Bruker also introduces multiple new solutions for the MALDI Biotyper RUO/GP systems to the U.S. market that were recently launched at ESCMID Global 2026, including the MBT Easy T ® Kit (GP), MBT Compass HT RUO/GP v.500 with an expanded library covering 5,325 species, and the MBT HT Library Creator (RUO). The latest RUO/GP library expansion adds more than 600 new species, including ~30% improved coverage of filamentous fungi, addressing a challenge in microbiology. The MBT HT Library Creator (RUO) Module lets laboratories generate, manage and share custom libraries within the MBT Compass HT environment, for research purposes. New classifiers for the IR Biotyper ® are also being introduced, further enhancing rapid outbreak investigation and surveillance capabilities.

These portfolio expansions are complemented by advances in next-generation sequencing (NGS) and molecular diagnostics. The MBioSEQ ® Ridom Typer software (RUO) - being introduced to the U.S. market at ASM 2026 - supports reflex NGS testing as an extension of microbial identification and outbreak analysis workflows. Together, the MALDI Biotyper, IR Biotyper, and MBioSEQ Ridom Typer reflex testing form a cohesive workflow that enables laboratories to progress from identification to epidemiological insight and genomic characterization.

“We believe the future of microbiology lies in integrated innovations that can deliver faster, clinically actionable answers for some of the most critical patient conditions, including sepsis,” said Carla Schneider, Bruker’s Director Commercial Operations, Microbiology & Infection Diagnostics - Americas. “At ASM Microbe 2026, we are showcasing how our expanding portfolio and innovation pipeline are helping laboratories move toward faster decision-making - including the next wave of solutions for rapid positive blood culture analysis. This is reflected in our U.S. microbiology business, where robust demand for MALDI Biotyper and IR Biotyper solutions drove 140 new system placements in 2025, complemented by double‑digit consumables growth. We’ve seen this double-digit US growth momentum continue into 2026, with both systems and consumables performing strongly.”

At ASM Microbe 2026, Bruker invites attendees to discuss how our expanding portfolio and work-in-progress developments are shaping microbial and molecular diagnostics. For more information about ASM Microbe, visit https://asm.org/events/asm-microbe/home .

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com .

Source: Bruker Corporation
## Recent Company News
- 2026-07-15 11:00 EST — [Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood](https://biopharmsignal.com/news/BRKR/bruker-expands-infection-detection-portfolio-with-acquisition-of-metagenomic-mng-36c3ebd1) — Source: Bruker
- 2026-06-25 13:46 EST — [Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026](https://biopharmsignal.com/news/BRKR/bruker-showcases-expanding-microbiology-and-infection-diagnostics-portfolio-at-asm-microbe-2026) — Source: Bruker
- 2026-06-25 13:46 EST — [Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry](https://biopharmsignal.com/news/BRKR/bruker-launches-new-timsmrms-mass-spectrometry-platform-for-unique-ultra-complex-mixture-applications-in-the-energy-industry) — Source: Bruker
- 2026-06-25 13:46 EST — [Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology](https://biopharmsignal.com/news/BRKR/bruker-announces-major-strides-in-4d-proteomics-performance-further-advances-in-intact-and-top-down-functional-proteoform-analysis-and-innovations-in-hybrid-qual-quant-4d-metabolomics-all-to-enable-deeper-insights-into-disease-biology) — Source: Bruker
- 2026-06-25 13:46 EST — [Champalimaud Foundation’s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI](https://biopharmsignal.com/news/BRKR/champalimaud-foundation-s-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri) — Source: Bruker
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)